Evidence-based two-and-seven criteria according to tumor number and size best help to predict survival of patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization

被引：0
|
作者：
Xia, D. [1 ]
Bai, W. [1 ]
Huang, M. [2 ]
Sun, J. [3 ,4 ]
Wang, E. [1 ]
Li, H. [5 ]
Li, J. [6 ,17 ]
Zhao, H. [7 ]
Pan, X. [8 ]
Chen, S. [9 ]
Gong, W. [10 ]
Zhu, X. [11 ]
Shao, G. [12 ]
Mu, W. [13 ]
Chen, Z. [14 ]
Wu, J. [15 ]
Liu, J. [16 ]
Li, J. [6 ,17 ]
Song, J. [18 ]
Zhang, C. [19 ]
Shi, H. [20 ]
Li, Z. [21 ]
Yang, S. [22 ]
Wang, W. [1 ,23 ]
Zheng, Y. [24 ]
Xu, J. [25 ]
Wang, W. [1 ,23 ]
Yuan, J. [1 ]
Li, X. [1 ]
Niu, J. [1 ]
Yin, Z. [1 ]
Fan, D. [1 ,26 ]
Xia, J. [27 ]
Han, G. [1 ]
机构：
[1] Forth Mil Med Univ, Xijing Hosp Digest Dis, Dept Liver Dis & Digest Intervent Radiol, Xian, Peoples R China
[2] Kunming Univ, Tumor Hosp Yunnan Prov, Affiliated Hosp 3, Dept Minimally Invas Int Therapy, Kunming, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary, Hangzhou, Zhejiang, Peoples R China
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Pancreat Intervent Ctr, Hangzhou, Zhejiang, Peoples R China
[5] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Intervent Radiol, Zhengzhou, Peoples R China
[6] Third Mil Med Univ, Xinqiao Hosp, Dept Hepatobiliary Surg, Chongqing, Peoples R China
[7] Nantong Univ, Affiliated Hosp, Dept Intervent Radiol, Nantong, Peoples R China
[8] Peoples Liberat Army, Hosp 180, Clin Liver Dis Res Ctr, Quanzhou, Peoples R China
[9] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Prov Canc Hosp, Dept Intervent Radiol, Nanjing, Jiangsu, Peoples R China
[10] Forth Mil Med Univ, Dept Intervent Radiol, Tangdu Hosp, Xian, Peoples R China
[11] Soochow Univ, Dept Intervent Radiol, Affiliated Hosp 1, Suzhou, Peoples R China
[12] Zhejiang Prov Tumor Hosp, Dept Intervent Radiol, Hangzhou, Zhejiang, Peoples R China
[13] Third Mil Med Univ, Southwest Hosp, Dept Radiol, Chongqing, Peoples R China
[14] Fujian Med Univ, Affiliated Hosp 1, Dept Intervent Radiol, Fuzhou, Peoples R China
[15] Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[16] Hunan Prov Peoples Hosp, Dept Intervent Radiol & Vasc Surg, Changsha, Hunan, Peoples R China
[17] Sun Yat Sen Univ, Dept Intervent Radiol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China
[18] Shandong Prov Tumor Hosp, Dept Intervent Therapy, Jinan, Peoples R China
[19] Shandong Univ, Shandong Prov Hosp, Dept Gastroenterol & Hepatol, Jinan, Peoples R China
[20] Nanjing Med Univ, Dept Intervent Radiol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
[21] Qingdao Univ, Affiliated Hosp, Intervent Med Ctr, Qingdao, Peoples R China
[22] Xinjiang Med Univ, Dept Intervent Radiol, Affiliated Tumor Hosp, Urumqi, Peoples R China
[23] Lanzhou Univ, Affiliated Hosp 1, Dept Intervent Med, Lanzhou, Peoples R China
[24] Yantai Yuhuangding Hosp, Dept Intervent Radiol, Yantai, Peoples R China
[25] Nanjing Mil Command, Nanjing Gen Hosp, Dept Med Imaging, Nanjing, Jiangsu, Peoples R China
[26] Fourth Mil Med Univ, Xijing Hosp Digest Dis, State Key Lab Canc Biol, Xian, Peoples R China
[27] Forth Mil Med Univ, Dept Hlth Stat, Xian, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)30292-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PS-020
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 40 条
  • [31] A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization
    Liu, Chang
    Li, Lei
    Lu, Wu-sheng
    Du, Hua
    Yan, Lu-nan
    Wen, Tian-fu
    Wei, Wu-ran
    Jiang, Li
    Xu, Ming-qing
    BMC CANCER, 2018, 18
  • [32] Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization
    Liu, Ying
    Shi, Menting
    Chen, Shuanggang
    Wan, Weiqi
    Shen, Lujun
    Shen, Binyan
    Qi, Han
    Cao, Fei
    Wu, Ying
    Huang, Tao
    Chen, Guanjian
    Mo, Jinqing
    Ye, Dongdong
    Zhang, Yinqi
    Feng, Ziqing
    Fan, Weijun
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (03) : 740 - 748
  • [33] Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control
    Popovic, Peter
    Stabuc, Borut
    Jansa, Rado
    Garbajs, Manca
    RADIOLOGY AND ONCOLOGY, 2016, 50 (04) : 418 - 426
  • [34] Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate- Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis
    Zhou, Churen
    Chang, Boyang
    Xiang, Zhanwang
    Li, Zhengran
    Wu, Chun
    Bai, Mingjun
    Jiang, Zaibo
    Huang, Mingsheng
    Chen, Junwei
    ACADEMIC RADIOLOGY, 2024, 31 (11) : 4456 - 4465
  • [35] Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study
    Toro, Adriana
    Ardiri, Annalisa
    Mannino, Maurizio
    Arcerito, Maria Concetta
    Mannino, Giovanni
    Palermo, Filippo
    Bertino, Gaetano
    Di Carlo, Isidoro
    BMC SURGERY, 2014, 14
  • [36] Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study
    Adriana Toro
    Annalisa Ardiri
    Maurizio Mannino
    Maria Concetta Arcerito
    Giovanni Mannino
    Filippo Palermo
    Gaetano Bertino
    Isidoro Di Carlo
    BMC Surgery, 14
  • [37] Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review
    Gao, Heng-Jun
    Xu, Li
    Zhang, Yao-Jun
    Chen, Min-Shan
    CHINESE JOURNAL OF CANCER, 2014, 33 (05) : 259 - 264
  • [38] Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization:report of two cases and literature review
    HengJun Gao
    Li Xu
    YaoJun Zhang
    MinShan Chen
    ChineseJournalofCancer, 2014, 33 (05) : 259 - 264
  • [39] Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study
    Ueshima, Kazuomi
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Kato, Naoya
    Yamashita, Tatsuya
    Shimose, Shigeo
    Numata, Kazushi
    Kodama, Yuzo
    Tanaka, Yasuhito
    Kuroda, Hidekatsu
    Itoh, Shinji
    Aikata, Hiroshi
    Hiraoka, Atsushi
    Moriguchi, Michihisa
    Wada, Yoshiyuki
    Nakao, Kazuhiko
    Tateishi, Ryosuke
    Ogasawara, Sadahisa
    Yamamoto, Kouji
    Ikeda, Masafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo plus bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE)-unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-seven criteria
    Yamashita, T.
    Ueshima, K.
    Tsuchiya, K.
    Kato, N.
    Shimose, S.
    Numata, K.
    Kodama, Y.
    Ohkawa, K.
    Kuzuya, T.
    Ikeda, M.
    Kooka, Y.
    Aikata, H.
    Hiraoka, A.
    Moriguchi, M.
    Fujiwara, K.
    Suda, G.
    Mochida, S.
    Ogasawara, S.
    Yamamoto, K.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1483 - S1484
1234